🚨 **Alzheimer’s Medication Alert** 🚨
New research is shaking up what we thought we knew about Alzheimer’s meds! A recent review suggests that drugs designed to slow the progression of Alzheimer’s might not make a “meaningful difference” for patients. 🤔 Plus, these medications may increase the risk of brain swelling and bleeding.
Researchers examined 17 studies with over 20,000 patients, mostly in their early 70s, who were dealing with early-stage Alzheimer’s or dementia. The findings showed that the impact on cognitive function was “trivial” after 18 months. 📉🧠
But hold on! Not everyone is on board with these conclusions. Some experts and charities argue that grouping older, unsuccessful drug trials with newer ones paints an overly gloomy picture. They say drugs like lecanemab and donanemab do offer “modest but meaningful” benefits for those in the early stages. 💊✨
The UK regulator gave these meds the green light, but they’ve been excluded from NHS use, citing cost-benefit concerns. Meanwhile, the long-term impact of side effects remains uncertain, especially since most studies wrapped up after just 18 months.
🚨 **What experts are saying:**
– Prof Edo Richard warns that the benefits might be too minor for patients and their families to notice.
– Dr Richard Oakley says we shouldn’t be too quick to dismiss decades of research.
– Dr Susan Kohlhaas stresses the importance of even a short delay in disease progression as valuable time for families.
The medicines watchdog is revisiting the decision to give these drugs another look. This could be a game-changer in Alzheimer’s treatment, so stay tuned! 🕵️♀️🔍
Alzheimer’s treatments are still evolving, aiming at new targets beyond amyloid plaques. We’re not at the finish line, but hope’s on the horizon! 🌈💪
Share your thoughts or personal experiences below! 👇 #Alzheimers #HealthNews #MedicalResearch #Innovation